Literature DB >> 15695339

High-throughput screening method of inhibitors that block the interaction between 2 helical regions of HIV-1 gp41.

Bong-Suk Jin1, Won-Kyu Lee, Kwangseog Ahn, Myung Kyu Lee, Yeon Gyu Yu.   

Abstract

The HIV-1 envelope glycoprotein transmembrane subunit, gp41, mediates the fusion of viral and target cell membranes. The 2 helical regions in the ectodomain of gp41, the N-helix and the C-helix, form a helical bundle complex that has been suggested as a fusion-active conformation. Previously, an enzyme-linked immunosorbent assay (ELISA) method had been established to measure the interaction of 2 helical regions of gp41. In this study, the ELISA method was modified to apply high-throughput screening (HTS) of an organic compound library. A few compounds had been identified to prevent the interaction between 2 helical regions of gp41, and they were further shown to inhibit the gp41-mediated viral infection. In addition, they specifically quenched the fluorescence of tryptophan in the N-helix region, indicating that these compounds bound to the N-helix rather than the C-helix of gp41. These results suggested that this assay method targeting gp41 could be used for HTS of HIV fusion inhibitors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15695339     DOI: 10.1177/1087057104269726

Source DB:  PubMed          Journal:  J Biomol Screen        ISSN: 1087-0571


  5 in total

1.  A novel fluorescence intensity screening assay identifies new low-molecular-weight inhibitors of the gp41 coiled-coil domain of human immunodeficiency virus type 1.

Authors:  Lifeng Cai; Miriam Gochin
Journal:  Antimicrob Agents Chemother       Date:  2007-04-23       Impact factor: 5.191

Review 2.  Neurobiological applications of small molecule screening.

Authors:  Andras Bauer; Brent Stockwell
Journal:  Chem Rev       Date:  2008-05-01       Impact factor: 60.622

3.  Antiviral peptides targeting the west nile virus envelope protein.

Authors:  Fengwei Bai; Terrence Town; Deepti Pradhan; Jonathan Cox; Michel Ledizet; John F Anderson; Richard A Flavell; Joanna K Krueger; Raymond A Koski; Erol Fikrig
Journal:  J Virol       Date:  2006-12-06       Impact factor: 5.103

4.  Design and characterization of an engineered gp41 protein from human immunodeficiency virus-1 as a tool for drug discovery.

Authors:  Kent D Stewart; Kevin Steffy; Kevin Harris; John E Harlan; Vincent S Stoll; Jeffrey R Huth; Karl A Walter; Emily Gramling-Evans; Renaldo R Mendoza; Jean M Severin; Paul L Richardson; Leo W Barrett; Edmund D Matayoshi; Kerry M Swift; Stephen F Betz; Steve W Muchmore; Dale J Kempf; Akhter Molla
Journal:  J Comput Aided Mol Des       Date:  2007-02-09       Impact factor: 3.686

5.  Structure-based design, synthesis and biological evaluation of new N-carboxyphenylpyrrole derivatives as HIV fusion inhibitors targeting gp41.

Authors:  Yong Wang; Hong Lu; Qiang Zhu; Shibo Jiang; Yun Liao
Journal:  Bioorg Med Chem Lett       Date:  2009-11-05       Impact factor: 2.823

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.